In the IV model of MV4–11 FLT3 AML, which mimics human AML pathophysiology, BKT300 significantly reduced the percentage of AML cells in both the blood (74.8% inhibition, Fig. 7H) and BM (72% inhibition, Fig. 7J), while increasing the number of normal mouse cells in the BM (2-fold increase) and blood (7-fold increase), compared to control mice (Fig. 7I, 7K). This evidence concerns the gene FLT3 and acute myeloid leukemia.